



Randall Moon is Director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington, School of Medicine in Seattle. He is also Professor of Pharmacology and the William and Marilyn Connor Chair at the University of Washington, School of Medicine. Randall Moon is also a scientific founder of Fate Therapeutics, a private biotech company interrogating adult stem cell biology and which applies induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds which guide cell fate for therapeutic purposes.

His research focuses on the roles of Wnt signal transduction in development and disease. Prof Moon's lab aims to identify the role of Wnt signaling in adults that will shed light on whether the control of cellular processes in embryos differs from that in adults and subsequently understand how Wnt signaling is linked to diseases. Results of his work have led to a better understanding of Wnt signaling in retinal diseases, cancer therapy and Alzheimer's disease and to identification of a promising new approach to treatment of metastatic melanoma. The Moon laboratory pioneered technologies of small interfering RNAs (siRNAs) directed against more than 30,000 target RNAs to elucidate whether reduction of any of the target RNAs would modulate β -catenin-responsive luciferase reporter in human cells.

<http://www.termis.org/eu2010/keynote.php>